Akero Sees Across-The-Board NASH Benefit With Efruxifermin, But Faces Competition

 
• By Joseph Haas
  
Competitive edge and business advantage concept as a group of hot air balloons racing to the top but an individualleader with a small balloon attached giving the winning competitor an extra boost.
Akero hopes to stay ahead of other FGF21 analogs in NASH
Scrip Podcast

Have you checked out Scrip podcast?

New episodes every Thursday.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business